Search Results

Ribometrix today announced it will present two posters with preclinical data highlighting advancements across two distinct modalities at the 2024 American Association for Cancer Research (AACR) Annual Meeting.

Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, shared the full data from two posters highlighting advancements across two distinct modalities presented at the 2024 American Association for Cancer Research Annual Meeting, held April 5-10 in San Diego, CA.

Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, today presented preclinical data supporting the potential of its eIF4E inhibitors in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium (SABCS), held December 5-9, 2023, in San Antonio, TX.

Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, today announced it will present preclinical data showing anti-tumor benefit of eIF4E inhibition in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium, held December 5-9, 2023, in San Antonio, TX.

Ribometrix today disclosed its lead wholly-owned development program targeting the protein eIF4E, and announced it will present initial preclinical data demonstrating the anti-tumor benefit of eIF4E inhibition at the 20th International Congress of the Society for Melanoma Research (SMR), held November 6-9, 2023, in Philadelphia, PA.